| Spontaneous Glioblastoma Spheroid Infiltration of Early-Stage Cerebral Organoids Models Brain Tumor Invasion |
17 |
| Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening |
17 |
| 3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis |
16 |
| OCTN: A Small Transporter Subfamily with Great Relevance to Human Pathophysiology, Drug Discovery, and Diagnostics |
14 |
| Transfer Learning with Deep Convolutional Neural Networks for Classifying Cellular Morphological Changes |
13 |
| Clinical Trials in a Dish: A Perspective on the Coming Revolution in Drug Development |
12 |
| Use of a High-Throughput Phenotypic Screening Strategy to Identify Amplifiers, a Novel Pharmacological Class of Small Molecules That Exhibit Functional Synergy with Potentiators and Correctors |
11 |
| Screening Approaches for Targeting Ribonucleoprotein Complexes: A New Dimension for Drug Discovery |
11 |
| Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9 |
10 |
| Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1 |
10 |
| A Therapeutic Role for the F1FO-ATP Synthase |
10 |
| A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1 |
9 |
| Drug Discovery on Natural Products: From Ion Channels to nAChRs, from Nature to Libraries, from Analytics to Assays |
9 |
| Randomness in DNA Encoded Library Selection Data Can Be Modeled for More Reliable Enrichment Calculation |
8 |
| Agonists and Antagonists of Protease-Activated Receptor 2 Discovered within a DNA-Encoded Chemical Library Using Mutational Stabilization of the Target |
8 |
| Robustness of In Vitro Selection Assays of DNA-Encoded Peptidomimetic Ligands to CBX7 and CBX8 |
8 |
| Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective |
7 |
| Amino Acid Transporters as Disease Modifiers and Drug Targets |
7 |
| A Fully Automated High-Throughput Flow Cytometry Screening System Enabling Phenotypic Drug Discovery |
7 |
| Using Physicochemical Measurements to Influence Better Compound Design |
6 |
| Influence of Matrigel on Single- and Multiple-Spheroid Cultures in Breast Cancer Research |
6 |
| Establishing MALDI-TOF as Versatile Drug Discovery Readout to Dissect the PTP1B Enzymatic Reaction |
6 |
| Nuisance Compounds, PAINS Filters, and Dark Chemical Matter in the GSK HTS Collection |
6 |
| Plate-Based Phenotypic Screening for Pain Using Human iPSC-Derived Sensory Neurons |
6 |
| Identification of an Arginase II Inhibitor via RapidFire Mass Spectrometry Combined with Hydrophilic Interaction Chromatography |
6 |
| SLC6A a Pivotal Actor on Cancer Stage: When Function Meets Structure |
5 |
| A Cytotoxic Three-Dimensional-Spheroid, High-Throughput Assay Using Patient-Derived Glioma Stem Cells |
5 |
| Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement |
5 |
| Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery? |
5 |
| High-Throughput Surface Liquid Absorption and Secretion Assays to Identify F508del CFTR Correctors Using Patient Primary Airway Epithelial Cultures |
5 |
| Implementation of the NCI-60 Human Tumor Cell Line Panel to Screen 2260 Cancer Drug Combinations to Generate >3 Million Data Points Used to Populate a Large Matrix of Anti-Neoplastic Agent Combinations (ALMANAC) Database |
5 |
| Three-Dimensional Leukemia Co-Culture System for In Vitro High-Content Metabolomics Screening |
5 |
| Screening Strategies and Methods for Better Off-Target Liability Prediction and Identification of Small-Molecule Pharmaceuticals |
4 |
| Enzyme-Inhibitor Interactions and a Simple, Rapid Method for Determining Inhibition Modality |
4 |
| Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools |
4 |
| High-Throughput Screening for Linear Ubiquitin Chain Assembly Complex (LUBAC) Selective Inhibitors Using Homogenous Time-Resolved Fluorescence (HTRF)-Based Assay System |
4 |
| Stabilization of Human Multidrug Resistance Protein 4 (MRP4/ABCC4) Using Novel Solubilization Agents |
4 |
| Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2 |
4 |
| Chemical Derivatization Enables MALDI-TOF-Based High-Throughput Screening for Microbial Trimethylamine (TMA)-Lyase Inhibitors |
4 |
| MyoScreen, a High-Throughput Phenotypic Screening Platform Enabling Muscle Drug Discovery |
4 |
| Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth |
4 |
| Identification of Poly(ADP-Ribose) Polymerase Macrodomain Inhibitors Using an AlphaScreen Protocol |
4 |
| Identification and Characterization of a New Series of Ghrelin O-Acyl Transferase Inhibitors |
4 |
| A Liquid Chromatography/Mass Spectrometry Method for Screening Disulfide Tethering Fragments |
4 |
| A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-6-Bisphosphate Aldolase |
4 |
| Identification and Characterization of Inhibitors of a Neutral Amino Acid Transporter, SLC6A Using Two Functional Cell-Based Assays |
4 |
| Identification of G-Quadruplex-Binding Inhibitors of Myc Expression through Affinity Selection-Mass Spectrometry |
4 |
| Use of Protein Kinase-Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors |
4 |
| A Robust Multiplex Mass Spectrometric Assay for Screening Small-Molecule Inhibitors of CD73 with Diverse Inhibition Modalities |
3 |
| Development of an Inhibitor Screening Assay for Mono-ADP-Ribosyl Hydrolyzing Macrodomains Using AlphaScreen Technology |
3 |
